Click here to download our corporate presentation
About Us
Biophytis is leading the development of new classes of therapeutics that make the body more resilient to stress to provide people with age-related and genetic diseases an enhanced quality of life.
Our Science
Our library of molecules, large collection of disease models, and academic collaborations, position us as leaders in the discovery of new compounds that promote resilience to stress to combat age-related and genetic degenerative diseases.
Pipeline
Our clinical stage pipeline includes SARCONEOS, a MAS receptor activator to preserve mobility in sarcopenic and Duchenne muscular dystrophy patients, and MACUNEOS, a drug that binds PPAR to slow vision decline in people with dry age-related macular degeneration.
News
17 April 2019

Interview with Stanislas Veillet, CEO of Biophytis, on the Web TV www.labourseetlavie.com realized by the journalist Didier Testot

16 April 2019

Biophytis announces the release of the 2018 Annual Financial Report and the departure of Jean-Gérard Galvez from the Board of Directors. Read the Press Release